Provenance
Written by SPS and the College of Sexual and Reproductive Healthcare (CoSRH), with the support of specialist stakeholders working within clinical practice, for use within reproductive services.
August 2025 – note the Faculty of Sexual and Reproductive Healthcare (FSRH) has now changed its name to the College of Sexual and Reproductive Healthcare (CoSRH). Some web pages and CoSRH documents will continue to display the FSRH name; where you see FSRH, this refers to CoSRH. All weblinks are still active.
PGD template attachment
The template PGD is attached below to download and use in conjunction with our implementation advice (SPS page).
More reproductive health PGD templates
- Etonogestrel (e.g. Nexplanon®) implant for contraception
- Combined hormonal contraceptive transdermal patch
- Combined hormonal contraceptive vaginal ring
- Medroxyprogesterone acetate (DMPA) SC injection for contraception
- Progestogen only pill (POP) for contraception
- Progestogen-Only Intra-Uterine Device (LNG-IUD) for contraception
- Combined oral hormonal contraceptive (COC) in reproductive health
- Ulipristal acetate 30mg tablets for emergency contraception
- Levonorgestrel 1500 microgram tablets for emergency contraception
- Lidocaine injection for subdermal etonogestrel in contraception
- Lidocaine plus prilocaine cream for IUD insertion or removal
- Lidocaine 10mg/ml spray for IUD insertion or removal
- Copper Intrauterine Device (Cu-IUD)
All PGD templates
National PGD, protocol and written instructions templates
National templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.
Update history
- Republished
- PGD template Version 3.1 published reflecting CoSRH CEU statement on meningioma. Previous versions removed due to expiry.
- Information added regarding CoSRH statement on Meningioma and Progestogens
- Republished
- Revised template to reflect minor clarifications following feedback.
- New Version 3.0 published
- Planned review detail added
- Information added regarding name change of FSRH to CoSRH
- Updated version 2.3 added. Updated contraindications and cautions in line with Sayana Press® SPC. Reworded to align with the PGD for administration of DMPA via the subcutaneous route.
- Updated PGD template published - statement added regarding a suggested link between the prolonged use of medroxyprogesterone acetate and a small increased risk of intracranial meningioma in line with FSRH statement. Added exclusion of meningioma as per SPC.
- Version 2.1 published - minor updates to reflect updated FSRH guidance
- V1 removed as expiring 31/7/23
- Title, URL and summary amended.
- New V2.0 template added
- Published